CytomX SVP Belvin granted RSUs and stock options

CytomX Therapeutics reported new equity awards for SVP and Chief Scientific Officer Marcia Belvin.

Rhea-AI Filing Summary

CytomX Therapeutics reported new equity awards for SVP and Chief Scientific Officer Marcia Belvin. On February 2, 2026 she received 60,000 restricted stock units of common stock at a price of $0, increasing her directly held common stock to 332,252 shares, including 218,958 RSUs.

She was also granted a stock option for 250,000 shares of common stock with a $6.09 exercise price. The option vests in equal monthly installments over four years starting from February 2, 2026, and the RSUs vest in three equal annual installments beginning March 15, 2027, subject to continued service.

Insider Trade Summary

Grant/Award: 310,000 shares

Grant/Award 2 txns

Insider BELVIN MARCIA

Role SVP, Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	250,000	$0.00	$0.00
Grant/Award	Common Stock	60,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 250,000 contracts (Direct); Common Stock — 332,252 shares (Direct)

Footnotes (3)

1. F1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date.
2. F2. Includes 218,958 RSUs.
3. F3. 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity awards were reported for CytomX (CTMX) SVP Marcia Belvin?

Marcia Belvin received 60,000 restricted stock units of CytomX common stock at a price of $0 and a stock option for 250,000 shares at a $6.09 exercise price, both granted on February 2, 2026 as part of her compensation.

How do the new RSUs affect Marcia Belvin’s CytomX (CTMX) share holdings?

The 60,000 new RSUs increase Marcia Belvin’s directly held common stock to 332,252 shares. This total includes 218,958 RSUs, each convertible into one share of CytomX common stock upon vesting, aligning her compensation with the company’s future share performance.

What is the vesting schedule for Marcia Belvin’s CytomX (CTMX) RSUs?

The RSUs vest in three equal installments. One-third vests on March 15 each year, with the first one-third vesting on March 15, 2027. Vesting is conditioned on Marcia Belvin continuing as a service provider through each applicable vesting date with CytomX Therapeutics.

How do Marcia Belvin’s new CytomX (CTMX) stock options vest?

The 250,000-share stock option vests monthly over four years. One forty-eighth of the option vests on each monthly anniversary of February 2, 2026, so the option becomes fully vested and exercisable on the fourth anniversary, subject to her continued service to CytomX.

What is the exercise price and term of Marcia Belvin’s CytomX (CTMX) stock option?

The stock option has a $6.09 exercise price per share of CytomX common stock. It was granted on February 2, 2026 and is scheduled to expire on February 1, 2036, giving a ten-year term, assuming vesting and other conditions are satisfied.

Does Marcia Belvin directly hold the CytomX (CTMX) securities reported in this Form 4?

Yes. The Form 4 shows both the common stock, including RSUs, and the 250,000-share stock option as directly owned by Marcia Belvin. No indirect ownership entities or disclaimers of beneficial ownership are indicated in the provided disclosure or its footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 04:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BELVIN MARCIA

(Last) (First) (Middle)

C/O CYTOMX THERAPEUTICS, INC.

151 OYSTER POINT BLVD., STE. 400

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CytomX Therapeutics, Inc. [ CTMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		A		60,000(1)	A	$0	332,252(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.09	02/02/2026		A		250,000		(3)	02/01/2036	Common Stock	250,000	$0	250,000	D

Explanation of Responses:

1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date.

2. Includes 218,958 RSUs.

3. 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

	/s/ Christopher Ogden, as Attorney-in-Fact for Marcia Belvin	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.